European Society for Blood and Marrow Transplantation
The EBMT Scientific Council, together with the local organizing committee, design an outstanding program to cover key issues relating to hematopoietic stem cell transplant and cellular therapy research.
Filter by content:
Types
- AL amyloidosis
- Chromosomal aberrations
- COVID-19
- Deletion 17p
- Gain 1q
- High-risk
- Newly diagnosed multiple myeloma
- Plasma cell dyscrasias
- Plasma cell leukemia
- Relapsed/refractory multiple myeloma
- Risk
- Smoldering multiple myeloma
- Solitary plasmacytoma
- Translocation (11;14)
- Translocation (14;16)
- Translocation (14;20)
- Translocation (4;14)
Therapeutics
- Allo-HSCT
- Auto-HSCT
- Auto-NKT
- BCMA CAR-T
- Bortezomib
- CAR therapy
- Carfilzomib
- Cellular therapy
- Ciltacabtagene autoleucel
- Cyclophosphamide
- Daratumumab
- Dexamethasone
- Doxorubicin
- Fludarabine
- Idecabtagene vicleucel
- Isatuximab
- Ixazomib
- Lenalidomide
- Melflufen
- Melphalan
- NKG2D CAR-T
- Plerixafor
- Pomalidomide
- Selinexor
- T-cell engagers
- Thalidomide
- Venetoclax
- Vincristine
Congresses
- 2021 Symposium
- ASCO 2019
- ASH 2017
- ASH 2019
- EBMT 2019
- EBMT 2020
- EBMT 2021
- EBMT 2022
- EBMT 2023
- EBMT 2024
- EBMT 2025
- ESH 2019
Trials
- APOLLO
- CARTITUDE-2
- CARTITUDE-4
- CASSIOPEIA
- GEM-CESAR
- GRIFFIN
- ICARIA-MM
- IFM2009
- IKEMA
- KarMMa
- MAIA
- MASTER
- Myeloma X
- OPTIMUM
- PERSEUS
- POLLUX
Expert Opinions
- Brea Lipe
- Bruno Paiva
- Chengcheng Fu
- Elena Zamagni
- Enrique Ocio
- Hermann Einsele
- Karthik Ramasamy
- Katja Weisel
- Laurent Garderet
- María-Victoria Mateos
- Meral Beksaç
- Mohamad Mohty
- Morie Gertz
- Nico Gagelmann
- Nicolaus Kröger
- Nikhil Munshi
- Nina Shah
- Noopur Raje
- Paul Richardson
- Philippe Moreau
- Sagar Lonial
- Sara Ghorashian
- Sergio Giralt
- Stefan Knop
Educational Resources
- Diagnostic and treatment guidelines
- Risk scores and prognostic tools
- Supportive care
Articles
51st Annual Meeting of the EBMT congress coverage
Catch up with our live social media coverage of multiple myeloma from the 51st Annual Meeting
Date: Apr 8, 2025Auto-HCT in newly diagnosed MM with del(17p): real-world outcomes
During the 50th Annual Meeting of the EBMT, Marcoux presented real-life outcomes of auto-HCT
Date: May 21, 2024EBMT 2024: Latest updates from CARTITUDE-2 and CARTITUDE-4
We summarize presentations by Tessa Kerre and Roberto Mina from the 50th Annual Meeting
Date: May 17, 2024CARTITUDE-2 Cohort C: Efficacy and safety of cilta-cel in patients with relapsed/refractory MM
We summarize the latest efficacy and safety findings of cilta-cel in patients with progressive
Date: May 25, 2023Supportive care in multiple myeloma: managing fatigue, cognitive impairment, and psychological wellbeing
Multiple myeloma (MM) accounts for 10% of all hematologic malignancies. During the 48th Annual
Date: May 30, 2022In the era of upfront quadruplets, is there still a role for allogeneic transplant?
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Date: May 17, 2022Novel risk score for predicting early relapse in patients with multiple myeloma
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated
Date: Apr 28, 2022Challenges and future directions for access to cell therapies: A global perspective
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EB)
Date: Apr 26, 2022Key concepts when talking about cure of multiple myeloma
The use of the term ‘cure’ in the field of multiple myeloma (MM) remains controversial
Date: Apr 30, 2021What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplanta
Date: May 12, 2021Which therapies are most frequently used in triple-exposed patients with MM?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EB
Date: Apr 9, 2021